The Nonalcoholic Steatohepatitis (NASH) ASPIRE program will evaluate submitted research proposals that cover areas in basic, clinical and translational sciences. Innovative, feasible, rigorous research proposals with the potential of high impact in advancing the learning about NASH will be prioritized.

Individual projects requesting up to USD $140,000 will be considered. Pfizer anticipates awarding up to 3 grants and a total fund of USD $420,000. Research is expected to be completed and submitted for presentation/publication within 2-3 years of study start.

The following are the main areas of priority with high unmet needs.   In adult patients with NASH:

• Biopsy-confirmed NASH prevalence, clinical outcomes, and healthcare utilization
• Innovations in the use of non-invasive tools in the care of patients with NASH
• Understanding genetic drivers of NASH and identification of risk factors for disease progression in NASH
• Real world evidence on current unmet need in patients with NASH and type 2 diabetes and/or obesity 

Learn more about this grant by reading the RFP (pdf)